Phase II clinical trial of interleukin-2, interferon-alpha and tegafur uracil therapy for advanced renal cell cancer
Phase 2
- Conditions
- advanced renal cell cancer
- Registration Number
- JPRN-UMIN000002222
- Lead Sponsor
- Department of Urology Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
(1)uncontrolled DM (2)ischemic heart disease (3)allergic reaction to IL-2 and/or IFN-alpha (4)auto-immune disease (5)patients having Shou-Sai-Kotou (special herbal drug) and/or steroids (6)depression (7)Investigator determines as unsuitable
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method anti-tumor response
- Secondary Outcome Measures
Name Time Method Time to progression, duration of response, overall survival, servival at home, performance status